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Background
Integrase defective lentiviral vectors (IDLV) represent a
promising delivery system for immunization purposes.
Human dendritic cells (DC) are the main cell types
mediating the immune response and are readily trans-
duced by IDLV, allowing effective triggering of in vitro
expansion of antigen-specific primed CD8+ T cells.
However, DC transduction efficiency is hindered by the
presence of SAMHD1 restriction factor, which inhibits
viral DNA synthesis.
Methods
IDLV expressing Flu-M1 containing simian immunode-
ficiency virus (SIV)-Vpx was produced and titred on
293T by standard methods. Monocytes from HLA-
A*0201 and M1-positive selected donors were differen-
tiated into DC and transduced with IDLV-M1/Vpx and
control IDLV/M1 or left untreated. IDLV-transduced
DC were co-cultured with autologous PBMC and the
expansion of M1-specific CD8+ T cells was analysed by
pentamer staining and IFNg ELISPOT
Results
The addition of the SIV-Vpx protein during IDLV pre-
paration resulted in a striking improvement of IDLV
transduction of human DC, thus increasing the ability of
IDLV-transduced DC to act as functional antigen pre-
senting cells, as evaluated by pentamer staining and
IFNg ELISPOT, in the absence of vector integration.
Importantly, the presence of SIV-Vpx allows for the use
of lower amount of input vector preparation, further
improving the safety profile of IDLV.
Conclusion
These results have important implications for the devel-
opment of vaccine strategies based on the use of IDLV
as a novel, safe and efficient delivery system.
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